We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon
Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
To Bill and all: Here's some news, although a little belated. Hambrecht & Quist posted their healthcare conference picks on January 20th and EVTI garnered a strong buy, medical product analyst Robert Faulker's number one pick for 1997. He sees price at $20 by year's end. That may have accounted for the little bump we experienced last week. More info at: hambrecht.com
Go to H&Q's searchable database on homepage for additional info on EVTI.
Thanks for the post. The most recent H&Q report that I found was Mar. 1996. ANy more recent? I basiclly like everything I have seen, except I believe( but am not sure) that Baxter is working on a completing product. Is this correct? If so do you know anything re a compare and contrast? US Surgical vs. J&J is what i keep remembering. Please let me know any thouhts you may have.
If the URL I posted doesn't take you directly to the material, go to hambrecht.com and select the transcript of the Jan 6-9 conference from near the top of the homepage. Lots of interesting general stuff here on 1997 lookout for biotechs, besides the EVTI mention. Also, search the database for more info on the company.
I don't know about competition but H&Q claims EVTI is way out in front of the game. Looks like years of cash burn ahead before the company hits the black, but of course, price often rises or falls on each stage of clinical phase results. I'll post again should I learn more.
It appears the street didn't care for this news. Checking Zacks I see where mgt missed annual expectations (actual: -1.66, estimate: 1.60), and last qtr (actual: -.49, estimate: -.43). Other news sounds OK.